Suchitra Sundaram

Has grant

Assistant Professor

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Suchitra Sundaram is an Assistant Professor at the Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, USA. Her research areas focus on hematological malignancies, with recent articles addressing treatment strategies for mantle cell lymphoma, Burkitt lymphoma, and the impact of COVID-19 on patients with these conditions. She is actively involved in exploring innovative therapeutic approaches and outcomes in various B-cell malignancies.

Recent Grants

Grant: Close

Evaluation of Clonal Hematopoiesis in Long Term Survivors of Diffuse Large B Cell Lymphoma after Cytotoxic Chemotherapy

Open Date: 2021-04-01

Close Date: 2023-10-31

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Helen Parry

Senior Clinical Lecturer/Associate Professor

University of Birmingham

UNITED KINGDOM

View details

Elizabeth Phillips

The University of Manchester

UNITED KINGDOM

View details

Mark Bower

Professor

Chelsea and Westminster Hospital

UNITED KINGDOM

View details

Matthew Wilson

University of Glasgow

UNITED KINGDOM

View details

Max Gordon

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Suchitra Sundaram

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory DLBCL.

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.

Burkitt Lymphoma International Prognostic Index.

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.

Collaborators (5)

Helen Parry

Elizabeth Phillips

Mark Bower

Matthew Wilson

Max Gordon

Make your next move.